PRWeb The Leader Press Release Distribution
See How PRWeb Works

We're here to help 1-866-640-6397

Login Create Free Account


All Press Releases for November 23, 2005 Subscribe to this News Feed    
 

Leading Providers of RUSH Immunotherapy, Sublingual Immunotherapy and Bioidentical Hormone Treatment Sign Exclusive Agreement for Vietnamese Treatment Facility Expansion

The Roby Institute and Schaupp Pte. Ltd announce exclusive agreement for the excusive licensing of effective RUSH Immunotherapies in Vietnam.

Austin, TX (PRWEB) November 23, 2005 -- The Roby Institute and Schaupp Pte. Ltd (a health care provider domiciled in Vietnam) announced to internet marketing and PR firm Global VIP Traffic an agreement authorizing the exclusive licensing and use of The Roby Institute Allergy and RUSH Immunology therapies today.

Headquartered in Austin, TX, with treatment facilities in San Antonio, Marble Falls and Austin, The Roby Institute is a world wide leader in RUSH Immunotherapy, SLIT, Neutralization and Bioidentical Hormone Treatment therapies. These noninvasive therapies offer immediate and significant relief for a wide range of chronic conditions, such as, migraine, pain, allergy, Asthma, Rheumatoid Arthritis, Chronic Fatigue (CFS), Fibromyalgia Syndrome (FMS), Weight Loss & Control, Menopause and Andropause related symptoms. Bioidentical Hormone Treatment has become more widely popular due to the release and promotion of Suzanne Somers’ new book, The Sexy Years, in which she describes how Bioidentical Hormone Treatment relieved her menopausal symptoms.    

Capitalizing on the successful performance of Dr. Roby’s Sublingual Immunotherapy, Bioidentical Hormone Treatment and RUSH Immunotherapy, Schaupp Pte. Ltd, intends to open 10 treatment facilities throughout Vietnam. Dr. Dat Vu, Director of Clinic operations, commented, “We reviewed and selected The Roby Institute modalities in light of their almost instant RUSH Immunotherapy positive results, ease of training and use, and broad spectrum of conditions that can be treated.”

The agreement also paves the way for H5n1 (bird flu) treatments and to be researched and developed in Vietnam. Recent news about this potential pandemic and the lack of available treatment options further increase the importance of this cooperative effort by the two companies.

The Roby Institute would not release further specific expansion plans at this time. Agreements are, however, expected over the course of the next two quarters in the European Union, South America, Eastern Europe and Asia.

About The Roby Institute
Dr. Russell Roby founded the Texan Allergy Center in Austin, Texas to assist residents of the Greater Austin area in combating allergy symptoms like nasal congestion, eye redness and soreness, sneezing, wheezing, coughing, pain, rashes/irritation, attention deficit disorder, and loss of short term memory. Dr. Roby is a world leader in Sublingual Immunotherapy, RUSH Immunotherapy and Bioidentical Hormone Treatment.

In 1995, www.OnlineAllergyCenter.com was launched to provide allergy sufferers with helpful information and tips online.

Contact
Sandra Pickard
General Manager
www.DrRoby.com
512-338-4336

# # #

Technorati Tags

Bookmark -  Del.icio.us | Furl It | Technorati | Ask | MyWeb | Propeller | Live Bookmarks | Newsvine | TailRank | Reddit | Slashdot | Digg | Stumbleupon | Google Bookmarks | Sphere | Blink It | Spurl


OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
Email this story to a colleague
CONTACT INFORMATION
Joe Perez
GLOBAL VIP TRAFFIC
7022530098
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your PRWeb News Management Console.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.